GSK-568859

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-568859
Drug Alias NameSB-568859568859GSK-568859
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipoprotein-associated phospholipase A2 inhibitors
TargetsLipoprotein-associated phospholipase A2
Therapy Area/IndicationsAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A